ACUR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACUR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Acura Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2021 was $0.00 Mil. Acura Pharmaceuticals's average total debt for the quarter that ended in Dec. 2021 was $0.26 Mil. Therefore, Acura Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2021 was 0.00%.
The historical data trend for Acura Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 14.81 | 11.42 | 9.04 | 7.34 | 6.18 |
Acura Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
Effective Interest Rate on Debt % | Get a 7-Day Free Trial | 7.15 | 7.06 | 9.75 | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's Effective Interest Rate on Debt % falls into.
Acura Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2021 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (A: Dec. 2020 ) | + | Total Debt (A: Dec. 2021 )) | / count ) |
= | -1 * -0.2 | / | ( (6.269 | + | 0.2) | / 2 ) |
= | -1 * -0.2 | / | 3.2345 | |||
= | 6.18 % |
where
Total Debt (A: Dec. 2020 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.105 | + | 6.164 |
= | 6.269 |
Total Debt (A: Dec. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.167 | + | 0.033 |
= | 0.2 |
Acura Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2021 is calculated as
Effective Interest Rate on Debt % | ||||||
= | -1 * Interest Expense | / | ( (Total Debt (Q: Sep. 2021 ) | + | Total Debt (Q: Dec. 2021 )) | / count ) |
= | -1 * 0 | / | ( (0.324 | + | 0.2) | / 2 ) |
= | -1 * 0 | / | 0.262 | |||
= | 0.00 % |
where
Total Debt (Q: Sep. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.291 | + | 0.033 |
= | 0.324 |
Total Debt (Q: Dec. 2021 ) | |||
= | Long-Term Debt & Capital Lease Obligation | + | Short-Term Debt & Capital Lease Obligation |
= | 0.167 | + | 0.033 |
= | 0.2 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2021) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.
Acura Pharmaceuticals (OTCPK:ACUR) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Thank you for viewing the detailed overview of Acura Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce F Wesson | director | 1827 PACIFIC ST BROOKLYN NY 11233 |
William G Skelly | director | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 |
George K Ross | director | 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596 |
James F Emigh | officer: VP, Corporate Development | |
Immanuel Thangaraj | director | 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380 |
Robert A Seiser | officer: VP, Treasurer & Controller | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 |
Robert B Jones | officer: President & CEO | C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067 |
Albert W Brzeczko | officer: VP Pharmaceutical Sciences APT | C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067 |
Peter A Clemens | officer: Senior VP & CFO | C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233 |
Abuse Deterrent Pharma, Llc | 10 percent owner | 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202 |
Claudius Llc | 10 percent owner | C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
John Schutte | 10 percent owner | 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233 |
Galen Partners Iii L P | 10 percent owner | 610 FIFTH AVE 5TH FL NEW YORK NY 10020 |
Galen Management, Llc | 10 percent owner | 680 WASHINGTON BLVD, STAMFORD CT 06901 |
Galen Employee Fund Iii Lp | 10 percent owner | 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
From GuruFocus
By Marketwired Marketwired • 06-14-2021
By Marketwired Marketwired • 03-31-2020
By Marketwired Marketwired • 10-01-2019
By Marketwired Marketwired • 06-30-2020
By Marketwired Marketwired • 02-28-2020
By Marketwired Marketwired • 09-09-2019
By gurufocus • 07-31-2009
By GuruFocusNews GuruFocusNews • 03-01-2022
By TipRanks TipRanks • 11-04-2014
By gurufocus 10qk • 10-26-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.